308 related articles for article (PubMed ID: 36630897)
1. Immunoglobulin Light Chain Amyloidosis: Diagnosis and Risk Assessment.
Zanwar S; Gertz MA; Muchtar E
J Natl Compr Canc Netw; 2023 Jan; 21(1):83-90. PubMed ID: 36630897
[TBL] [Abstract][Full Text] [Related]
2. Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2018 Sep; 93(9):1169-1180. PubMed ID: 30040145
[TBL] [Abstract][Full Text] [Related]
3. Systemic Amyloidosis Due to Clonal Plasma Cell Diseases.
Bianchi G; Kumar S
Hematol Oncol Clin North Am; 2020 Dec; 34(6):1009-1026. PubMed ID: 33099420
[TBL] [Abstract][Full Text] [Related]
4. [Light chain amyloidosis].
Hegenbart U; Aus dem Siepen F; Schönland S
Inn Med (Heidelb); 2023 Sep; 64(9):842-847. PubMed ID: 37540260
[TBL] [Abstract][Full Text] [Related]
5. New developments in diagnosis, risk assessment and management in systemic amyloidosis.
Vaxman I; Dispenzieri A; Muchtar E; Gertz M
Blood Rev; 2020 Mar; 40():100636. PubMed ID: 31706583
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome.
Tovar N; Rodríguez-Lobato LG; Cibeira MT; Magnano L; Isola I; Rosiñol L; Bladé J; Fernández de Larrea C
Amyloid; 2018 Jun; 25(2):79-85. PubMed ID: 29482381
[TBL] [Abstract][Full Text] [Related]
7. Amyloid consults do not have to be vexing.
D'Souza A
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):407-412. PubMed ID: 38066929
[TBL] [Abstract][Full Text] [Related]
8. [Detection of abnormal plasma cells in bone marrow contributes to the diagnosis of primary systemic light chain amyloidosis-review].
Hu Y; Zhu P
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1251-5. PubMed ID: 23114159
[TBL] [Abstract][Full Text] [Related]
9. Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition.
Muchtar E; Dispenzieri A; Lacy MQ; Buadi FK; Kapoor P; Hayman SR; Gonsalves W; Warsame R; Kourelis TV; Chakraborty R; Russell S; Lust JA; Lin Y; Go RS; Zeldenrust S; Rajkumar SV; Dingli D; Leung N; Kyle RA; Kumar SK; Gertz MA
Ann Med; 2017 Nov; 49(7):545-551. PubMed ID: 28271734
[TBL] [Abstract][Full Text] [Related]
10. An interesting case of AL amyloidosis and MM: a complex scenario with cardiac involvement.
Gaba M; Kumar N; Pandey A; Dewan A
BMJ Case Rep; 2024 Jan; 17(1):. PubMed ID: 38272507
[TBL] [Abstract][Full Text] [Related]
11. Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden.
Schwotzer R; Manz MG; Pederiva S; Waibel C; Caspar C; Lerch E; Flammer AJ; Brouwers S; Seeger H; Heimgartner R; Fehr T; Rossi D; Bianchi E; Stüssi G; Ghilardi G; Gerber B
Hematol Oncol; 2019 Dec; 37(5):595-600. PubMed ID: 31486522
[TBL] [Abstract][Full Text] [Related]
12. The value of screening biopsies in light-chain (AL) and transthyretin (ATTR) amyloidosis.
Cohen OC; Sharpley F; Gilbertson JA; Wechalekar AD; Sachchithanantham S; Mahmood S; Whelan CJ; Martinez-Naharro A; Fontana M; Lachmann HJ; Hawkins PN; Gillmore JD
Eur J Haematol; 2020 Sep; 105(3):352-356. PubMed ID: 32495369
[TBL] [Abstract][Full Text] [Related]
13. Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2024 Feb; 99(2):309-324. PubMed ID: 38095141
[TBL] [Abstract][Full Text] [Related]
14. Hepatic AL Amyloidosis without Significant Light Chain Elevation in a Patient Treated with CyBorD Plus Daratumumab.
Rybinski B; Kocoglu M
Am J Case Rep; 2021 Aug; 22():e933241. PubMed ID: 34421115
[TBL] [Abstract][Full Text] [Related]
15. Management of the elderly patient with AL amyloidosis.
Nuvolone M; Milani P; Palladini G; Merlini G
Eur J Intern Med; 2018 Dec; 58():48-56. PubMed ID: 29801808
[TBL] [Abstract][Full Text] [Related]
16. Patterns of target organ amyloid deposition in patients with AL amyloidosis; role for diagnosis and prognosis.
Fotiou D; Theodorakakou F; Malandrakis P; Ntanasis-Stathopoulos I; Gavriatopoulou M; Kanellias N; Migkou M; Eleutherakis-Papaiakovou E; Papanikolaou A; Gakiopoulou C; Terpos E; Dimopoulos MA; Kastritis E
Leuk Lymphoma; 2023 Jun; 64(6):1212-1215. PubMed ID: 37035896
[No Abstract] [Full Text] [Related]
17. Successful Treatment of Systemic Light Chain Amyloidosis with Liver Involvement using Low-Frequency Daratumumab: A Case Report.
Meng X; He J; Cheng F; Yan H; Zhu C; Guo X; Li Y; Cai Z; He D
Am J Case Rep; 2024 Jan; 25():e942534. PubMed ID: 38229422
[TBL] [Abstract][Full Text] [Related]
18. Light-chain cardiac amyloidosis for the non-expert: pearls and pitfalls.
De Michieli L; Sinigiani G; De Gaspari M; Branca A; Rizzo S; Basso C; Trentin L; Iliceto S; Perazzolo Marra M; Cipriani A; Berno T
Intern Emerg Med; 2023 Oct; 18(7):1879-1886. PubMed ID: 37338717
[TBL] [Abstract][Full Text] [Related]
19. Presence of fluorescent in situ hybridization abnormalities is associated with plasma cell burden in light chain amyloidosis.
Hammons L; Brazauskas R; Pasquini M; Hamadani M; Hari P; D'Souza A
Hematol Oncol Stem Cell Ther; 2018 Jun; 11(2):105-111. PubMed ID: 28830801
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in the management of AL Amyloidosis.
Kastritis E; Dimopoulos MA
Br J Haematol; 2016 Jan; 172(2):170-86. PubMed ID: 26491974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
